Alzheimer disease is the most common form of neurodegenerative disease. The onset of the disease is associated with the formation of senile plaques that are a pathological marker of the disorder. The primary constituent of the plaques is the aggregated peptide ␤ amyloid (A␤), 3 a 39 -43-amino acid peptide derived from amyloid precursor protein (APP). A␤ is generally accepted as being toxic and as such is a key therapeutic target as well as a diagnostic marker. Recent evidence suggests that altered metal homeostasis is a key factor in the etiology of Alzheimer disease (1) (2) (3) (4) (5) and other neurodegenerative conditions such as Creutzfeldt-Jakob and Parkinson diseases (6) . Both copper and zinc induce aggregation of neurotoxic A␤ (7) . In addition, biometals modulate the structure and redox activity of both the parental APP and the prion protein involved in Creutzfeldt-Jakob disease (6, 8) . Because of the importance of metals in neurodegenerative diseases, research has been directed toward harnessing the capability of metal-complexing ligands as therapeutic agents (9, 10) . Important progress has been made with the cell-permeable ligand clioquinol (cq), which has been shown to inhibit amyloid plaque formation in brains of APP transgenic mice (11) . Subsequent early phase IIa clinical trials have been promising (12) . However, little is known about the in vivo mechanism of action of cq.
In a recent study, we investigated the influence of M II (cq) 2 complexes upon A␤ metabolism in cell culture (13) . Cu II (cq) 2 and Zn II (cq) 2 were taken up by the cells, triggering activation of phosphoinositol 3-kinase (PI3K) and subsequent phosphorylation of the downstream target molecules Akt and glycogen synthase kinase 3 (GSK3). Mitogen-activated protein kinases (MAPKs) (such as JNK and extracellular signal-regulated kinase (ERK)) were also activated. This resulted in the up-reg-* This work was supported by the National Health and Medical Research ulation of matrix metalloproteases (MMPs) and the degradation of extracellular A␤ (13) . These findings demonstrated that cell-permeable metal transporting agents might be developed as therapeutic agents for modulation of A␤ turnover in AD patients. Metal complexes of cq cannot be given directly to patients via oral administration because of the moderate affinity of cq metal complexes (11) . As a result cq metal complexes offer little or no control over metal release and retention.
In an attempt to overcome this difficulty, we have been investigating the use of metal complexes of bis(thiosemicarbazone) (btsc) ligands (see Fig. 1 ). btsc complexes have been investigated as metallodrugs for a number of years and proven to have a broad range of pharmacological activity (14, 15) . In particular, recent interest has focused on the use of btsc ligands as vehicles for the selective delivery of radioactive copper isotopes to hypoxic tissue and leukocytes in assessment of their potential as radiopharmaceuticals (16, 17 (23) . However, differences in pK a values, and the stability of the reduced state to dissociation of the metal may also be important (24 -26) . Importantly, because of the ligand donor set (N 2 S 2 ), these ligands do not bind Ca II with any appreciable affinity and therefore should have no effect on other intracellular metals.
btsc complexes are also capable of transporting Zn II into cells, and the intrinsic fluorescence of certain Zn II (btsc) complexes has been used to probe their intracellular distribution in several lines of cancer cells (27) . Zn II , like Cu, is central to a number of cell signal pathways including modulation of N-methyl-D-aspartate receptor activity (28) , expression of metallothioneins (29, 30) and activation of MAPK-mediated signal transduction pathways (31) . It is apparent that both Cu II (btsc) and Zn II (btsc) uptake could have complex effects on downstream metal-mediated cell signaling. M II (btsc) complexes have a number of properties that make them worthy of investigation as potential therapeutic agents for AD. Several Cu II (btsc) complexes are capable of crossing the blood-brain barrier, and certain examples of the ligands have low toxicity (17, 23, 32) . Importantly, the ligands can be modified readily by varying the nature and number of alkyl substituents, and these modifications allow subtle control of subcellular targeting and metal release/retention properties. Therefore, we examined the ability of Cu II (btsc) and Zn II (btsc) complexes to deliver bioavailable metals to APP-CHO cells and how this affected A␤ turnover. Our studies found that intracellular release of zinc or copper from btsc complexes abrogated extracellular levels of A␤.
EXPERIMENTAL PROCEDURES

General Synthetic Procedures
The general synthetic procedures are described in the supplemental data.
Materials
5-Chloro-7-iodo-8-hydroxyquinoline (cq), Me 2 SO, neuocuproine (nc), LY294002, SB203580, and SP600125 were purchased from Sigma-Aldrich. GM6001, MMP inhibitor-I, MMP-2 inhibitor-I, and MMP-9 inhibitor-I were obtained from Merck. Antibodies to total or phospho-specific forms of Akt, JNK, and GSK3 were obtained from Cell Signaling Technology (Beverly, MA).
Methods
APP-transfected Chinese
Hamster Ovary Cells-APP-CHO cells were generated by expressing the 695-amino acid APP cDNA in the pIRESpuro2 expression vector (Clontech, Mountain View, CA) as described previously (13) . Transfected cells were maintained in RPMI 1640 medium supplemented with 1 mM glutamine and 10% fetal bovine serum (all from Invitrogen) selected and maintained using 7.5 g/ml puromycin (Sigma-Aldrich).
Exposure of Cells to M II (btsc)-APP-overexpressing cells were passaged at a ratio of 1:6 and grown in 6-or 12-well plates for 2-3 days before experiments. The cells were treated when ϳ90% confluent. M II (btsc), cq, and nc were prepared as 10 mM stock solutions in Me 2 SO and added to serum-free RPMI medium supplemented with puromycin as above. Basal metal levels in the medium were 0.5 and 1.3 M for copper and zinc, respectively, as determined by inductively coupled plasma mass spectrometry (ICP-MS). Additional metals were added where indicated, and medium was briefly mixed by aspiration prior to addition to cells. The control cultures were treated with vehicle (Me 2 SO) alone. Inhibitors of Akt, (LY294002), JNK (SP600125), p38 (SB203580), or metalloproteases (GM6001, MMP inhibitor I, MMP-2 inhibitor-I, and MMP-9 inhibitor-I) were prepared as 10 mM stock solutions in Me 2 SO and added at the indicated concentrations. The cultures were incubated for 6 h, and conditioned media were taken for measurement of A␤ levels by ELISA. For immunoblotting, the cells were harvested into Phosphosafe extraction buffer (Novagen) containing protease inhibitor mixture (Calbiochem) and stored at Ϫ80°C until use. Alternatively, the cells were washed three times with PBS and harvested for analysis of metal levels by ICP-MS.
Inductively Coupled Plasma Mass Spectrometry-The cells were treated with M II (btsc) for 6 h and washed three times with Chelex 100-treated PBS, pH 7.4. The cells were scraped into PBS, an aliquot was taken for protein determination (Protein Microassay; Bio-Rad), and the remaining cells were collected by centrifugation at 14,000 rpm for 2 min in a Hermle Microfuge (Labnet, Woodbridge, NJ). The metal levels were determined in cell pellets by ICP-MS as described previously and converted to fold increase in metal compared with untreated controls (37) .
Degradation of Synthetic A␤1-40-Human A␤1-40 was purchased from the W. Keck Laboratory (Yale University, New Haven, CT) and dissolved in Me 2 SO at 1 mg/ml. The dissolved peptide was further diluted into Chelex 100-treated dH 2 O at 100 ng/ml before addition to M17 neuroblastoma cell cultures in serum-free medium at 10 ng/ml without aging as previously reported (13) . After 6 h (with or without the addition of 25 M CuGTSM), medium was collected, and the remaining A␤1-40 levels were determined by ELISA.
Double Antibody Capture ELISA for A␤ Detection-A␤ levels were determined in culture medium using the DELFIA Double Capture ELISA. 384-well plates (Greiner, Frickenhausen, Germany) were coated with monoclonal antibody G210 in coating buffer (15 mM Na 2 CO 3 , 35 mM NaHCO 3 , pH 9.6) for A␤1-40 detection. The plates were washed with PBS containing 0.05% Tween (PBST) and blocked with 0.5% (w/v) casein. Biotinylated monoclonal antibody WO2 (epitope at A␤5-8) and culture medium or A␤ peptide standards were added (50 l) to each well and incubated overnight at 4°C. The plates were washed with PBST and streptavidin-labeled Europium (PerkinElmer Life Sciences) was added. The plates were washed, enhancement solution (PerkinElmer Life Sciences) was added, and the plates were read in a WALLAC Victor 2 plate reader with excitation at 340 nm and emission at 613 nm. A␤1-40 peptide standards and samples were assayed in triplicate. The values obtained from the triplicate wells were used to calculate the A␤ concentration (expressed as ng/ml) based on the standard curve generated on each plate.
Western Blot Analysis of Protein Expression and Phosphorylation-
Cell lysates prepared in Phosphosafe buffer were mixed with electrophoresis SDS sample buffer (Novex) and separated on 12% Novex SDS-PAGE Tris-glycine gels. The proteins were transferred to polyvinylidene difluoride membranes and blocked with milk solution in TBST before immunoblotting for total or phospho-specific proteins. For detection of signal transduction molecules, the membranes were probed with polyclonal antisera against JNK or phospho-JNK, Akt or phospho-Akt, GSK3␣, or phospho-GSK3␣/␤ all at 1:5000. Secondary antiserum was goat anti-rabbit horseradish peroxidase at 1:10,000. Blots were developed using Amersham Biosciences ECL Advance Chemiluminescence and imaged on a GeneGnome Chemiluminescence Imager (Syngene, Cambridge, UK). We found that the expression of total levels of kinases (Akt and JNK) was unaffected by metal uptake in APP-CHO cells. In contrast, actin, tubulin and other proteins normally used for equalizing protein loading were found to be altered depending on metal levels. 4 Therefore, equal sample loading and protein transfer was assessed by the consistency of total kinase protein levels on immunoblots rather than unrelated proteins. Statistical Analysis-The data are the means Ϯ S.E. from at least three separate experiments unless stated. The results were analyzed using the analysis of variance test. 2 resulted in lower levels of secreted A␤ from APP-CHO cells (13) . Therefore, we examined whether Cu II (btsc) complexes also affected A␤ levels by measuring extracellular A␤1-40 levels in the culture medium from the treated cells (13) . Treatment with the free ligands (btscH 2 ) and the Cu II (btsc) complexes had no significant effect on the level of A␤1-40 (Fig. 3) . In contrast, treatment with Cu II (cq) 2 and Cu II (nc) 2 resulted in a dose-dependent reduction in the levels of secreted A␤1-40 in the culture medium, confirming our previous study of Cu II (cq) 2 (13) . A small decrease in total APP expression was observed consistent with cq-treated APP-CHO cells (13) . However, this was insufficient to account for the loss of A␤ (80 -90%). The form of decreased extracellular A␤ detected by ELISA was monomeric. This was supported by the loss of monomeric A␤ in Cu II (gtsm)-treated cell culture medium by Western blot and is consistent with our previous report on cq inhibition of extracellular monomeric A␤ levels in APP-CHO cells (13) . Whether oligomers are also affected by Cu II (gtsm) is not known because these were not observed by Western blot, and the ELISA does not detect aggregated A␤. However, because there was a substantial loss of monomeric A␤ (ϳ90%), this is likely to preclude formation of higher oligomeric forms.
RESULTS AND DISCUSSION
The lack of effect of Cu II (btsc) complexes (featuring two alkyl substituents on the backbone of the ligand) on A␤ turnover may be related to their high thermodynamic stability (log K A ϭ 18) and their resistance to reductively assisted transchelation reactions (for example Cu(atsm): E 1/2 (Cu II /Cu I ) ϭ Ϫ0.59 V versus SCE) (23, 33, 34) . These properties would promote retention of structural integrity inside the cell, ensuring that the copper is not bioavailable. In comparison, less stable cell-permeable complexes such as Cu II (nc) 2 and Cu II (cq) 2 (log K A ϭ 9) are susceptible to dissociation of the metal from the ligand inside the cell (11) . Dissociation would allow the copper to become bioavailable and, as reported previously (13) , to participate in metal-mediated cell signaling pathways that ultimately result in degradation of A␤. (atsp), respectively. These analogues lacked the two methyl groups on the diimine backbone of the ligand (Fig. 1B) (Fig. 4A) . This result was expected for the cell-permeable copper complexes (cf. Fig. 2 ), but now there was a dose-dependent reduction in the extracellular levels of monomeric A␤1-40 (Fig. 4B) (Fig. 4B) . Small reductions in monomeric A␤1-40 levels were seen with the free ligands gtsmH 2 and gtspH 2 (Fig. 4B) . We speculate that this could be due to the formation of the Cu II and/or Zn II complexes from those metals available in the culture medium (0.5 copper and 1.3 M zinc). The metal-free gtsmH 2 is capable of binding free or loosely bound (bioavailable) Cu II or Zn II in the medium and transporting this metal into the cell. However, additional studies will be required to determine whether this process occurs and is sufficient to account for the level of A␤1-40 reduction observed in gtsmH 2 -treated cultures. Alternative interactions between the free ligand and cells or A␤1-40 also need to be investigated. Further studies revealed a dose-dependent reduction in the extracellular levels of monomeric A␤1-40 upon treatment with 1-50 M Cu II (gtsm) (Fig. 4C) . A significant reduction in A␤1-40 levels was observed with 1 M Cu II (gtsm), and this was further reduced to below the detection limit of the assay at the 25 and 50 M concentrations (Fig. 4C) . These results show that minor modification of the btsc backbone can crucially modify the chemical and biological behavior of the complex. The modifications still allowed Cu II (gtsm), Cu II (gtse), and Cu II (gtsp) to transport copper into cell (as for Cu II (atsm)) but, once inside, appear to permit reductively assisted dissociation of the copper from the ligand to give elevated levels of intracellular bioavailable copper.
Zn II (btsc) Complexes Induce Loss of Secreted A␤-We also examined the effect of Zn II (btsc) complexes on metal uptake and A␤ turnover. The cells were treated with four complexes (Fig. 1A; 25 M) , and this resulted in significant increases in the intracellular zinc levels as measured by ICP-MS (Fig. 5A) . Zn II (atsm) and Zn II (atse) induced 8.2 (Ϯ0.25)-and 9.8 (Ϯ0.9)-fold increases in cellular zinc levels, respectively, a result consistent with increased levels induced by the other cell-permeable complexes Zn II (cq) 2 and Zn II (nc) 2 (Fig. 5A) (13) . The lower stabilities of the Zn II (btsc) complexes (log K A ϭ 7) inferred that they were more susceptible to intracellular transchelation than their copper analogues and therefore elevate levels of bioavail- able zinc within the cells. The elevated zinc levels correlated with a reduction in the extracellular levels of monomeric A␤1-40 (Fig. 5B) . The concentration of A␤1-40 in the medium of untreated cells was 0.6 -0.8 ng ml Ϫ1 and was reduced to less than 0.2 ng ml Ϫ1 (the detection limit) following treatment with 25 (Fig. 5B) . This could reflect different binding affinities or different subcellular localization (which would initiate different metal-mediated cell signaling pathways).
We also examined the effect of zinc homologues of the gtsm, gtse, and gtsp ligands (Fig. 5C) . Interestingly, Zn II (gtsm) had no significant effect on cellular zinc levels (1.1 Ϯ 0.3-fold), possibly because of instability of the complex (Fig. 5C ). Zn II (gtse) induced a small but significant increase in zinc levels (2.6 Ϯ 0.03-fold), whereas Zn II (gtsp) had a greater effect, increasing cellular zinc by 15 Ϯ 0.5-fold. The zinc uptake corresponded to effects of these complexes on monomeric A␤1-40 levels. Zn II (gtsm) did not decrease A␤ levels in treated cultures, whereas Zn(gtse) had a modest effect (57 Ϯ 5% of controls), and Zn II (gtsp) greatly reduced A␤1-40 to 15 Ϯ 14% of controls (Fig. 5D) . Further support for the link between metal uptake and loss of A␤1-40 was obtained through our studies on transmetallation reactions and temperature-dependent uptake of M II (btsc) (see supplemental information).
M(btsc) Complexes Activate PI3K-and JNK-dependent Pathways Resulting in Metalloproteasemediated Degradation of Secreted A␤1-40-
We have shown previously that cell-permeable metal complexes can induce activation of PI3K-Akt-GSK3 and MAPK pathways resulting in up-regulation of MMP activity and degradation of secreted A␤ (13) . APP-CHO cells were treated with M II (btsc) (10 M; 6 h), and the cell lysates were examined for activation of PI3K and MAPK signal pathways. Cu II (atsp) and Cu II (atse) did not induce activation of PI3K (Akt phosphorylation) or JNK (Fig. 6A) , consistent with the lack of effect on A␤1-40 levels by these complexes (Fig. 3 ). In contrast, treatment with Zn II (atse) or Zn II (atsm) induced activation of Akt and JNK (Fig. 6A) . Activation of PI3K-Akt by Zn II (atse) also induced downstream phosphorylation (deactivation) of GSK3 and increased GSK3 expression (Fig. 6B) . These results were indistinguishable from the effects of Cu II (cq) 2 on APP-CHO cells (13) . Interestingly, Zn II (atsp) did not induce detectable activation of Akt or JNK (Fig. 6A) , although a small increase in GSK3 expression was observed (Fig. 6B) . Because Zn II (atsp) also induced a reduction in secreted A␤1-40 levels, it may affect different cell signaling pathways. Alternatively, Zn II (atsp), which is the only zinc complex tested that possesses an aromatic substituent, could directly interfere with detection of some phospho-proteins, consistent with the observed increase in GSK3 expression but poor detection of phospho-GSK3 (Fig. 6B) .
Treatment of cells with Cu II (gtsm) (25 M) reduced secreted monomeric A␤1-40 levels and also induced phosphorylation of Akt, JNK, and GSK3 (Fig. 6C) , whereas treatment with the (Fig. 6A ) and had no effect on secreted A␤1-40 levels, the data provide further support for the importance of PI3K-Akt-GSK3 and JNK activation in metal ligand-mediated inhibition of A␤. To further substantiate this hypothesis, APP-CHO cells were treated with Zn II (atse) (10 M) with and without specific inhibitors of PI3K (LY294002), JNK (SP600125), or p38 (SB203580) (25 M of each). These inhibitors blocked activation of PI3K, JNK, and p38, respectively, in APP-CHO cells treated with Cu II (cq) 2 (13) . Treatment with both LY294002 and SP600125 blocked the effect of treatment with Zn II (atse) and prevented the loss of A␤1-40 (Fig. 6D ). Treatment with SB203580 had no effect (Fig.  6D ) and was consistent with our recent finding that p38 activation is not involved in loss of A␤1-40 induced by metal complexes (13) .
The mechanisms by which metals activate these pathways is not known, but given the relatively large changes in intracellular metals involved, it is unlikely to involve direct enzymatic effects of copper or zinc Previous studies have demonstrated that MMP enzymes can degrade both human-derived and synthetic A␤ (35) , whereas MMP expression is altered in the brains of AD patients (36) . We have shown that Cu II (cq) 2 complexes induced PI3K-and JNK-mediated up-regulation of MMPs, and the increased MMP activity resulted in enhanced degradation of secreted A␤ (13) . To substantiate this, the effect of broad spectrum MMP inhibitors (GM6001, MMP inhibitor-I, and MMP-2 inhibitor-I) on A␤ levels was examined in cultures exposed to Zn II (atse) (10 M). Co-administration of each inhibitor (25 M) with Zn II (atse) increased significantly the level of secreted A␤ after 6 h when compared with treatment with Zn II (atse) alone (Fig. 6E) . In contrast, MMP-9 inhibitor-I had no effect on A␤ levels. These results are consistent with previous studies (13) showing that broad spectrum and MMP-2 inhibitors prevented a loss of secreted A␤ induced by Cu We have also reported recently that treatment of APP-CHO cells with alternative metal complexes had no effect on cellular A␤ levels or APP processing (37) . In the present study, no intracellular A␤ was observed (data not shown), consistent with previous reports (13, 37) that loss of extracellular A␤ is most likely induced by increased MMP synthesis. However, the oligomeric state of the secreted A␤ in our cultures has not been fully investigated. It is also possible that altered metal levels in the medium or cells could promote formation of higher oligomeric states of A␤ including dimers, trimers, etc. Because these are not routinely detectable by our Western blot or ELISA techniques, we cannot rule out the metal-mediated aggregation of A␤ as a factor contributing to the loss of detectable monomeric A␤ in the conditioned medium. Further studies will be needed to address this possibility. Finally, to confirm that these metal-btsc complexes inhibit A␤ levels in neuronal-like cells, we examined the effect of Zn II (atse) on levels of synthetic A␤1-40 added to the medium of neuronal-like cells. M17 cells were treated with 10 g/ml of A␤1-40 for 6 h with or without 25 M Zn II (atse). We found that Zn II (atse) treatment induced a significant decrease in the level of A␤ remaining in the conditioned medium (Fig. 7) . Co-treatment with the PI3K inhibitor LY294002 or MMP inhibitor GM6001 abrogated this effect, strongly suggesting that the loss of A␤ was mediated through increased MMP levels or activity (Fig. 7) .
Concluding Remarks-This study demonstrated that Cu II (btsc) complexes were capable of transporting Cu(II) into APP-CHO cells, and release of metals in the cell resulted in loss of extracellular A␤. Subtle but crucial modifications of the ligand backbone appear to permit controlled intracellular redox-mediated release of copper from the ligand. The released metal is then able to activate signaling pathways to decrease extracellular A␤ by MMPs (Fig. 8) .
A growing body of literature supports a central role for metals in the etiology of AD. Although studies have shown that extracellular metal accumulation may enhance A␤ deposition and toxicity, other studies indicate that copper supplementation by diet or genetic modification can lead to decreased A␤ deposition and improvement in cognition (2, 3) . The reason for this paradox is uncertain but may be related to an imbalance between intracellular and extracellular metal homeostasis. Age-related changes may lead to increased efflux of copper or zinc, promoting A␤ accumulation and decreasing activity of copper-dependent enzymes. In this context, restoration of intracellular copper levels could restore the imbalance and promote a decrease in A␤ accumulation. The mechanisms associated with this are not known but could potentially be mediated through increased A␤ degradation as shown here in vitro. However, in vivo studies are required to confirm this hypothesis.
Several recent studies have highlighted a potential role for modulating metal levels as a basis for AD therapy. Transgenic AD mice (Tg2576) treated with cq revealed marked decreases in cerebral amyloid load but elevated levels of cerebral copper and zinc (11) . Treatment with cq involves administration of a "free ligand" that must sequester a metal from a biological source if it is to activate the pathways outlined previously (13) and in this work. The "cq approach" involves attenuation of latent metal ion sinks and could result in nondiscriminate binding of essential metal ions in the biological milieu that could have deleterious side effects. Our present work presents a unique and alternative approach. Cell-permeable metal btsc complexes, not free ligands, were utilized, and the metal ion is released inside the cell. Because the complexes are already metal-loaded, there is no requirement for the complexes to strip metals from other sources that may have adverse consequences. The copper complexes are particularly attractive because the high stability of Cu II (btsc) complexes is coupled to the unique ability to control release of the metal ion via subtle changes to the ligand backbone. These changes alter the susceptibility of the complexes to undergo reductively assisted metal ion release, but this release only occurs inside the cell.
In this study, we found that relatively large changes in metal levels (ϳ100 -200-fold Cu II and ϳ10-fold Zn II ) were associated with the subsequent biological effects such as kinase activation and loss of monomeric A␤. Because these metals (Cu II and Zn II ) are normally involved in catalytic processes, the requirement for large changes in metal levels is unexpected. The reason for this is unknown but could reflect that fact that the metals may be acting in a noncatalytic manner such as oxidation of cysteine residues on certain proteins. Alternatively, a significant proportion of the metal taken up by the cells could be sequestered by metal binding molecules, thus preventing the interaction of the metal with processes leading to the loss of A␤. Interestingly, we reported recently that some metal complexes can activate kinase-dependent pathways and alter extracellular A␤1-40 levels with little or no change in overall cellular metal levels (37) . Further investigation is necessary to determine the mechanisms by which altered metal levels result in kinase activation and reduced A␤1-40 generation.
Other studies have reported that increased cerebral copper levels (through genetic manipulation or feeding regimes) similarly led to reduced amyloid deposition in transgenic AD mouse models (2, 3) . Our findings suggest that amyloid levels may be reversed by increases in intracellular metal levels resulting in up-regulation of A␤-degrading metalloproteases. Whether similar effects occur in vivo is yet to be determined. However, the potential to deliver copper as a complex to inhibit A␤ generation may prove to be a more favorable approach than dietary copper supplementation (3). These characteristics, coupled with our new results showing reduction in levels of A␤ in APP-CHO cells following treatment with Cu II (gts) derivatives and Zn II (btsc) complexes, suggest that these compounds have potential as therapeutic agents for AD.
